Genmab (GMAB) Collaboration summary

Opening remarks and agenda

• Broad oncology collaboration announced June 10, 2020, covering three bispecific antibody programs and a discovery research partnership.

• An English-language conference call was scheduled for June 10, 2020, with a live and archived webcast.

Objectives of the partnership

• Jointly develop and commercialize epcoritamab, DuoHexaBody-CD37 and DuoBody-CD3x5T4 to advance potential cancer therapies.

• Discover up to four additional differentiated antibody-based candidates for solid tumors and hematological malignancies.

Partner introductions and roles

• AbbVie brings clinical expertise, an ADC platform and global commercial leadership in hematological cancers; the collaboration adds next-generation bispecific antibody programs and discovery capabilities.

• Epcoritamab commercial responsibilities are shared in the U.S. and Japan, with AbbVie responsible for commercialization elsewhere; the originating party books U.S. and Japan net sales.

• For DuoHexaBody-CD37, DuoBody-CD3x5T4 and discovery-derived candidates, global development and commercialization responsibilities are shared; co-commercialization rights apply outside the U.S. and Japan.